Latest Loprazolam Stories
A study in the June 1 issue of the journal SLEEP demonstrates that online cognitive behavioral therapy (CBT) for chronic insomnia significantly improves insomnia severity, daytime fatigue, and sleep quality.
By Bill Berkrot NEW YORK (Reuters) - An experimental insomnia drug being developed by Merck & Co. and Danish drug maker H. Lundbeck A/S showed promise in helping patients achieve deep sleep in small mid-stage clinical studies, the companies said on Wednesday.
Ramelteon, a novel investigational compound under review with the FDA for the treatment of insomnia, reduced the time it took to fall asleep and increased total sleep time in adults with chronic insomnia, according to results from a Phase 3 study presented this week at the 19th Annual Meeting of the Associated Professional Sleep Societies (APSS). Results of the study also showed no evidence of rebound insomnia, next-day impairments or withdrawal effects due to discontinuation.
- A trick or prank.